




RealRate

# PHARMACEUTICAL 2021

ANI Pharmaceuticals INC  
Rank 234 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 238%, being 18% points below the market average of 256%.

| Input Variable                              | Value in<br>1000 USD | Output Variable             | Value in<br>1000 USD |
|---------------------------------------------|----------------------|-----------------------------|----------------------|
| Assets, Current                             | 170,321              | Assets                      | 461,190              |
| Cost of Goods Sold                          | 87,157               | Liabilities                 | 265,490              |
| Intangible Assets                           | 192,091              | Expenses                    | 221,077              |
| Liabilities, Current                        | 78,565               | Revenues                    | 208,475              |
| Liabilities, Non-Current                    | 186,925              | Stockholders Equity         | 195,700              |
| Other Assets                                | 57,509               | Net Income                  | -22,548              |
| Other Compr. Net Income                     | -6,566               | Comprehensive Net Income    | -25,831              |
| Other Expenses                              | 52,933               | BaseVar                     | 586,372              |
| Other Liabilities                           | 0                    | ECR before LimitedLiability | 110%                 |
| Other Net Income                            | -9,946               | Economic Capital Ratio      | 238%                 |
| Other Revenues                              | 208,475              |                             |                      |
| Property and Equipment                      | 41,269               |                             |                      |
| Research and Development                    | 16,001               |                             |                      |
| Selling, General and Administrative Expense | 64,986               |                             |                      |